SIGA
SIGA Technologies, Inc. NASDAQ$4.63
Mkt Cap $331.7M
52w Low $4.29
6.4% of range
52w High $9.62
50d MA $5.24
200d MA $6.88
P/E (TTM)
13.9x
EV/EBITDA
11.7x
P/B
1.7x
Debt/Equity
0.0x
ROE
11.7%
P/FCF
9.0x
RSI (14)
—
ATR (14)
—
Beta
1.06
50d MA
$5.24
200d MA
$6.88
Avg Volume
645.3K
About
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and acces…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 10, 2026 | AMC | — | -0.08 | — | 5.65 | +0.0% | -3.0% | -3.2% | -6.9% | -3.4% | -11.2% | — |
| Nov 6, 2025 | AMC | — | -0.09 | — | 8.17 | -10.6% | -20.0% | -20.3% | -23.0% | -24.0% | -25.6% | — |
| Aug 5, 2025 | AMC | — | 0.49 | — | 6.60 | +5.9% | +10.0% | +29.5% | +35.8% | +43.6% | +40.9% | — |
| May 8, 2025 | AMC | — | -0.01 | — | 5.44 | -0.7% | +4.0% | +9.2% | +9.2% | +9.0% | +8.8% | — |
| Mar 11, 2025 | AMC | — | 0.63 | — | 5.60 | +4.5% | +7.0% | -2.7% | -0.4% | +0.5% | +2.9% | — |
| Nov 7, 2024 | AMC | — | 0.02 | — | 7.63 | -0.1% | -0.8% | -1.2% | -7.5% | -13.4% | -17.4% | — |
| Aug 1, 2024 | AMC | — | 0.03 | — | 9.24 | -6.7% | -5.8% | -10.9% | -7.5% | -5.8% | -0.6% | — |
| May 7, 2024 | AMC | — | 0.14 | — | 10.46 | -1.9% | -28.3% | -25.9% | -28.7% | -28.8% | -25.0% | — |
| Mar 12, 2024 | AMC | — | 1.01 | — | 5.32 | +12.6% | +21.2% | +29.9% | +37.8% | +49.4% | +56.8% | — |
| Nov 7, 2023 | AMC | — | -0.01 | — | 5.16 | -11.2% | -6.6% | -4.7% | -4.5% | -5.2% | -4.3% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 6 | Wedbush | Maintains | Outperform → Outperform | — | $2.91 | $2.93 | +0.7% | +1.4% | -1.0% | -6.9% | -8.2% | -8.2% |
Recent Filings
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
SIGA filed an 8-K with minimal disclosed details, suggesting either a routine filing or withheld material information; investors should seek clarification on the actual announcement to assess relevance.
Mar 26
8-K
Unknown — 8-K Filing
SIGA's $88M TPOXX revenue in 2025 plus a $13M international order signal strong demand for its monkeypox treatment, suggesting sustained revenue growth and improved earnings visibility for the biotech stock.
Mar 10
Data updated apr 27, 2026 1:16am
· Source: massive.com